A Study of IBI362 in Participants With Obesity or Overweight

NCT05607680 · Completed

Last updated 2026-05-28

This clinical trial tests the safety and effects of the medication IBI362 in adults who have obesity or are overweight.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 610 people

Who can join Ages 18+ · all sexes

Timeline Started 2022-11 · est. completion 2024-04

Where 23 sites · China

What this study is testing ClinicalTrials.gov NCT05607680 ↗

Description as written by the study sponsor.

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 2-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Treatments tested

Placebo Drug

Placebo administered subcutaneously (SC) once a week.
IBI362 Drug

IBI362 administered subcutaneously (SC) once a week.

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Obesity Or Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05607680 ↗